Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

Keren Rouvinov, Karen Nalbandyan, Victor Kozlov, Nir Peled, Alexander Yakobson

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalCase Reports in Oncology
Issue number1
StatePublished - 1 Jan 2019
Externally publishedYes


  • Aplastic anemia
  • Immunotherapy
  • Melanoma
  • Nivolumab
  • Programmed death 1 inhibitor

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma'. Together they form a unique fingerprint.

Cite this